Draft:Nutcracker Therapeutics
Submission declined on 10 May 2024 by Samoht27 (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Submission declined on 29 December 2023 by Timtrent (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
|
Submission declined on 9 December 2023 by ToadetteEdit (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
|
Submission declined on 1 December 2023 by Stuartyeates (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
|
- Comment: Appears to not be an improvement. Toadette (Happy holiday!) 06:05, 9 December 2023 (UTC)
- Comment: Press releases, patents and article by staffers are not independent. Stuartyeates (talk) 19:02, 1 December 2023 (UTC)
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology..[1][2][3]. The technology, similar to "lab-on-a-chip" technology, uses single-use microfluidics biochips that encompass RNA molecule design, drug delivery, and biomanufacturing, and can efficiently produce small volumes of therapeutic mRNA in accordance to Good manufacturing practice (GMP)[2][4][5]. The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge[5]. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer[4]
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[6][7]. The therapeutic contains three RNA molecules: a molecule intended to elicit T cell response against HPV proteins E6 and E7, and two immunostimulatory RNA molecules that boost the therapeutic effect[5][6]. As of 2023, NTX-250 is in the preclinical stage of development.
References[edit]
- ^ Sullivan, Josh (March 14, 2022). "GMP-in-a-box company with Bob Nelsen backing lands $167M to develop its own cancer drugs". Endpoints News. Retrieved December 5, 2023.
- ^ a b Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478. PMID 35945442.
- ^ Glasner, Joanna (2022-06-29). "ARCH Venture Partners Raises $3B For Biotech". Crunchbase News. Retrieved 2024-02-08.
- ^ a b Lynn, Jessica (2022-08-24). "Nutcracker Therapeutics Creating RNA Therapies". Patient Worthy. Retrieved 2023-12-11.
- ^ a b c Golovin, Danielle; Writer, Staff. "Nutcracker: RNA design, delivery and manufacturing under one roof". BioCentury. Retrieved 2023-12-11.
- ^ a b Shaffer, Catherine (July 27, 2022). "Nutcracker Therapeutics Aims to Beat HPV-Driven Cancers With Multimodal mRNA Therapeutics". Precision Medicine Online. Retrieved December 1, 2023.
- ^ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.